Alzheimer's Disease and Dementia Early-Diagnostic Clinic Launched in Iceland

A new clinic powered by state-of-the-art, non-invasive biomarkers for the early, differential diagnosis of brain disorders, including Alzheimer's disease, Lewy Body and other common forms of dementia is launched in Iceland by EEG specialist MentisCura

Alzheimer's Disease and Dementia Early-Diagnostic Clinic Launched in Iceland

MentisCura Diagnostics ehfKristinn Gretarsson, +354 840 9143Chief Executive OfficerorTel: +354 530 9900

MentisCura Diagnostics () today announced the launch of its first clinical center for the early detection of Alzheimer's disease and other dementias. The operational launch brings sophisticated biomarkers capable of assisting early, differential diagnosis into a clinical setting and provides for the first time cutting edge electrophysiological analysis developed by MentisCura to the general public through community physicians.

Both the high prevalence and rapidly increasing incidence of CNS disorders are raising alarm on account of the growing burden of care associated with these diseases. According to data published by the Alzheimer's Association, Alzheimer's disease is the sixth-leading cause of death in the United States, with as many as one in eight older Americans having Alzheimer's disease in 2012. A recent World Alzheimer's Report estimated the 2010 worldwide cost of dementia to be more than $600bn.

“Our new service fulfills an important role addressing the key issues of earlier and more accurate diagnosis. Current diagnostic tools such as fMRI and PET are in a price range that precludes their use as screening tools for dementias. The low cost, high-throughput and non-invasive nature of our test makes it uniquely useful in a real world clinical setting, where physicians need to assess patients and make diagnostic decisions before these diseases have reached a late and untreatable stage. From a five-minute EEG recording using the international standard 10-20 testing protocol, our powerful analytical systems are able to provide same-day results back to physicians,” said Kristinn Gretarsson, CEO of MentisCura.

“MentisCura provides a welcome and reliable tool for diagnosing the causes of cognitive impairment and dementia. It plays a key role in our diagnostic protocol for dementia and is an important part of our follow up on disease progression and treatment efficacy,” commented Jon Snaedal, MD, Chief Physician of the Memory Clinic at the National Hospital of Iceland.

MentisCura's clinic offers a complete, integrated service to hospitals and general practitioners through sampling, processing and analysis of patient EEG data. The MentisCura Analysis System is a CE marked diagnostic aid, based on advanced, proprietary EEG-biomarker technology platform that accurately maps changes in electrophysiology to specific disease pathologies, through correlation with the world´s most comprehensive proprietary EEG database for dementia and cognitive disorders. The platform supports diagnoses for most common types of dementia, including Alzheimer's disease and Lewy Body Dementia.

MentisCura, based in Reykjavik, Iceland, is a privately held diagnostic company serving clinicians and pharmaceutical clients with state-of-the-art services and technology to improve and accelerate the differential diagnosis of CNS disorders.

MentisCura currently operates the world's first fully automated EEG-based biomarker service for clinicians through its own clinic and remotely via electronically transmitted EEG recordings.

MentisCura's service is based on a decade in the design, development and clinical validation of powerful algorithm-based biomarkers by its team of clinical specialists and neurophysiological experts. From a five minute EEG recording, MentisCura provides a fast and reliable assessment of the likelihood that a patient is suffering from dementia and the type, including Alzheimer's disease and Lewy Body Dementia.

MentisCura is working with leading distributors and key opinion leaders in the pharmaceutical industry and academia to expand the use of its technologies globally.

The MentisCura Analysis System is a CE marked product to comply with the provisions of the European Medical Device Directive 93/42/EEC (MDD).

For more information please visit: